HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VISEN PHARMA-B

33.160

-1.300-3.77%

Volume:32.60K

Turnover:1.11M

Market Cap:3.78B

PE:-17.04

High:36.700

Open:36.700

Low:33.000

Close:34.460

52wk High:69.150

52wk Low:32.800

Shares:114.00M

HK Float Shares:114.00M

Volume Ratio:1.48

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.946

ROE:-57.66%

ROA:-29.52%

PB:4.04

PE(LYR):-17.04

PS:4105.43

Loading ...

Overview Company News Filings

VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao

VISEN Pharmaceuticals Names CFO

MT Newswires Live

VISEN PHARMA-B (02561): Lu Ying Appointed as Chief Financial Officer

Visen Pharmaceuticals Appoints Lu Ying as New Chief Financial Officer

BRIEF-Visen Pharmaceuticals Appoints Lu Ying As CFO

Visen Pharmaceuticals - Appoints Lu Ying as CFO

THOMSON REUTERS

VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year

Innovative Drug Sector Maintains Strong Momentum, VISEN PHARMA-B (02561) Poised for "Davis Double Play"

Morgan Stanley: Enhanced Market Recognition of Biotech Stocks Drives Outperformance, Bullish on AKESO (09926) and Others

Visen Pharmaceuticals Expands Supply Agreement with Ascendis Group for Broader Product Access

VISEN Pharmaceuticals' H1 Loss Widens 41%

MT Newswires Live

BRIEF-Visen Pharmaceuticals Logs HY Loss RMB118 Mln

Visen Pharmaceuticals Reports Increased Loss of RMB 118 Million for H1 2025; R&D and Administrative Expenses Rise Significantly

VISEN PHARMA-B (02561) Reports Interim Results with R&D Costs of RMB 46.621 Million, Up 19.8% YoY

Visen Pharmaceuticals - Hy Loss RMB118 Mln

THOMSON REUTERS

Visen Pharmaceuticals Conducted Annual General Meeting

Visen Pharmaceuticals to Vote on Revised Proxy Proposal at Upcoming Shareholder Meeting

Visen Pharmaceuticals Secures New Supply Agreement with Ascendis Europe for Drug Packages and Auto-Injectors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02561/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"VISEN PHARMA-B","latestPrice":33.16,"timestamp":1763102162465,"preClose":34.46,"halted":0,"volume":32600,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"Trading","change":-1.3,"latestTime":"11-14 14:36:43","open":36.7,"high":36.7,"low":33,"amount":1112980,"amplitude":0.107371,"askPrice":33.16,"askSize":100,"bidPrice":33.1,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.238552,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1763107800000},"marketStatusCode":2,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":34.46,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":1.478434,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":1.478434,"shares":113999999,"dividePrice":0,"high":36.7,"amplitude":0.107371,"preClose":34.46,"low":33,"week52Low":32.8,"pbRate":"4.04","psRate":"4105.43","week52High":69.15,"institutionHeld":0,"latestPrice":33.16,"eps":-1.946273,"divideRate":0,"volume":32600,"delay":0,"ttmEps":-2.238552,"open":36.7,"prevYearClose":68.8,"prevWeekClose":36.46,"prevMonthClose":38.02,"prevQuarterClose":42.5,"fiveDayClose":36.46,"twentyDayClose":40.4,"sixtyDayClose":47.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746201600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-11-13","current":-15.39388,"percent":0.987013,"low":-30.760225,"twenty":-27.764882,"median":-26.313071,"eighty":-18.919941,"high":-14.784203,"avg":-24.499309,"sd":4.145138,"marketCap":3619036203},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412},{"date":"2025-07-25","current":-27.917728,"twenty":-28.10544,"median":-27.177054,"eighty":-25.808828,"marketCap":5582416336},{"date":"2025-08-01","current":-26.858726,"twenty":-28.252573,"median":-27.236899,"eighty":-25.835301,"marketCap":5337473578},{"date":"2025-08-08","current":-26.45431,"twenty":-28.168194,"median":-27.174901,"eighty":-25.937332,"marketCap":5270256728},{"date":"2025-08-15","current":-27.513449,"twenty":-28.142473,"median":-27.236899,"eighty":-26.012565,"marketCap":5473046546},{"date":"2025-08-22","current":-26.703746,"twenty":-28.118557,"median":-27.177054,"eighty":-26.021282,"marketCap":5295320638},{"date":"2025-08-29","current":-26.119434,"twenty":-28.10544,"median":-27.144467,"eighty":-26.021282,"marketCap":5204179147},{"date":"2025-09-05","current":-23.791598,"twenty":-28.093765,"median":-27.114576,"eighty":-25.835301,"marketCap":4735670561},{"date":"2025-09-12","current":-23.381705,"twenty":-28.083375,"median":-27.05699,"eighty":-25.694259,"marketCap":4662460107},{"date":"2025-09-19","current":-23.051901,"twenty":-28.060478,"median":-27.021811,"eighty":-25.478949,"marketCap":4593433106},{"date":"2025-09-26","current":-21.933119,"twenty":-28.003961,"median":-26.881441,"eighty":-23.835003,"marketCap":4359159651},{"date":"2025-10-03","current":-19.179371,"twenty":-27.951558,"median":-26.814509,"eighty":-23.612343,"marketCap":4545323379},{"date":"2025-10-10","current":-18.42629,"twenty":-27.909584,"median":-26.722604,"eighty":-23.450061,"marketCap":4360487033},{"date":"2025-10-17","current":-18.280755,"twenty":-27.87397,"median":-26.671617,"eighty":-23.093007,"marketCap":4322679342},{"date":"2025-10-24","current":-17.856771,"twenty":-27.855424,"median":-26.557884,"eighty":-22.535934,"marketCap":4223959260},{"date":"2025-10-31","current":-16.854881,"twenty":-27.829876,"median":-26.452186,"eighty":-21.933119,"marketCap":3992912259},{"date":"2025-11-07","current":-16.17341,"twenty":-27.822718,"median":-26.363703,"eighty":-19.806882,"marketCap":3829078931},{"date":"2025-11-13","current":-15.24303,"twenty":-27.764882,"median":-26.313071,"eighty":-18.919941,"marketCap":3619036203}],"updateTime":1763079555050},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1101244851","title":"VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao","url":"https://stock-news.laohu8.com/highlight/detail?id=1101244851","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101244851?lang=en_us&edition=fundamental","pubTime":"2025-11-03 10:28","pubTimestamp":1762136899,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2575060164","title":"VISEN Pharmaceuticals Names CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575060164","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575060164?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:35","pubTimestamp":1760358918,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (HKG:2561) named Lu Ying as its CFO effective Monday, a same-day Hong Kong bourse filing said.Lu served as the CFO of VivaVision Biotech from August 2021 to October 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"1174517174","title":"VISEN PHARMA-B (02561): Lu Ying Appointed as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1174517174","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174517174?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:58","pubTimestamp":1760349507,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) announced that Lu Ying has been appointed as the company's Chief Financial Officer, effective October 13, 2025.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2575647419","title":"Visen Pharmaceuticals Appoints Lu Ying as New Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575647419","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575647419?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:58","pubTimestamp":1760349498,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals has announced the appointment of Mr. Lu Ying as Chief Financial Officer, effective October 13, 2025. Mr. Lu brings over 19 years of financial management experience, having previously served as CFO at VivaVision Biotech Limited and held financial leadership roles at Allergan and Bayer Healthcare. The board of directors' composition remains unchanged, with Mr. Lu An-Bang continuing as Executive Director and CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL2ZfTkZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2575474955","title":"BRIEF-Visen Pharmaceuticals Appoints Lu Ying As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575474955","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575474955?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:54","pubTimestamp":1760349285,"startTime":"0","endTime":"0","summary":"BRIEF-Visen Pharmaceuticals Appoints Lu Ying As CFOOct 13 (Reuters) - Visen Pharmaceuticals 2561.HK:APPOINTS LU YING AS CFOFurther company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VT01G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2575747498","title":"Visen Pharmaceuticals - Appoints Lu Ying as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575747498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575747498?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:54","pubTimestamp":1760349263,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VT01G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"1188705635","title":"VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1188705635","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188705635?lang=en_us&edition=fundamental","pubTime":"2025-10-06 11:50","pubTimestamp":1759722636,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million. According to VISEN PHARMA's prospectus, the company's most...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"1171826434","title":"Innovative Drug Sector Maintains Strong Momentum, VISEN PHARMA-B (02561) Poised for \"Davis Double Play\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1171826434","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171826434?lang=en_us&edition=fundamental","pubTime":"2025-10-03 08:59","pubTimestamp":1759453188,"startTime":"0","endTime":"0","summary":"Since 2025, Hong Kong's pharmaceutical market has demonstrated structural outperformance, with the innovative drug sector becoming a focal point for capital allocation due to fundamental inflection...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","159992","02561","BK1574","BK1161"],"gpt_icon":0},{"id":"1177779820","title":"Morgan Stanley: Enhanced Market Recognition of Biotech Stocks Drives Outperformance, Bullish on AKESO (09926) and Others","url":"https://stock-news.laohu8.com/highlight/detail?id=1177779820","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177779820?lang=en_us&edition=fundamental","pubTime":"2025-09-23 10:04","pubTimestamp":1758593057,"startTime":"0","endTime":"0","summary":"Morgan Stanley released a research report stating that the total market capitalization of Chinese biotech stocks listed in Hong Kong has surged 154% year-to-date, significantly outpacing the Hang...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"079ddef7faa176ef1b029e2be2a3b56e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","HK0000252160.HKD","LU0348735423.USD","LU2328871848.SGD","LU2778985437.USD","LU2097828714.EUR","LU0455707207.USD","HK0000252152.HKD","BK1583","HK0000500386.USD","LU2476274720.SGD","LU1720050803.USD","LU0348783233.USD","02561","LU0417516902.SGD","01801","IE00BPRC5H50.USD","09969","159837","09926","LU0561508036.HKD","LU0634319403.HKD","LU2097828805.USD","LU2543165471.USD","BK1574","LU0348784397.USD","02256","LU0502904849.HKD","LU0417516738.SGD","09606","LU0348825331.USD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2097828557.USD","LU0348767384.USD","LU2097828631.EUR","LU2097828474.EUR","LU1794554557.SGD","IE00B543WZ88.USD","LU2242644610.SGD","LU0348766576.USD","BK1589","LU0540923850.HKD","LU2476274308.USD","BK1161","LU0417516571.SGD","LU0348827113.USD"],"gpt_icon":0},{"id":"2563722853","title":"Visen Pharmaceuticals Expands Supply Agreement with Ascendis Group for Broader Product Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2563722853","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563722853?lang=en_us&edition=fundamental","pubTime":"2025-08-31 20:17","pubTimestamp":1756642652,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals has announced a supplemental agreement to its existing Commercial Supply Framework Agreement with Ascendis Europe. This amendment, signed on August 29, 2025, allows VISEN HK and its subsidiaries to purchase drug packages, auto-injectors, and ancillary products from Ascendis A/S and its subsidiaries. The modification aims to enhance flexibility and resource allocation within the Ascendis Group, benefiting both parties involved. The announcement follows a previous circular issued on June 12, 2025, regarding the connected transactions under the original framework. Executive Director and CEO of Visen Pharmaceuticals, Mr. LU An-Bang, emphasized that aside from the disclosed changes, all other details of the agreement remain unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nNDL3VPCbm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2562070730","title":"VISEN Pharmaceuticals' H1 Loss Widens 41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562070730","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562070730?lang=en_us&edition=fundamental","pubTime":"2025-08-28 14:02","pubTimestamp":1756360959,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals  reported 118 million yuan in attributable loss for the first half of 2025, widening by 41% from a loss 83.5 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.Loss per share was 1.18 yuan, compared with 0.89 yuan in the prior year.It came as the company, which debuted on the Hong Kong bourse in March, continues to develop its core product called lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency.In July, the company partnered with Anhui Anke Biotechnology  to jointly promote the drug in specific regions of China.Shares of the pharmaceutical company fell 1.1% in midday trade Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK1161","02561","BK0070","BK0042","BK0239","300009"],"gpt_icon":0},{"id":"2562067740","title":"BRIEF-Visen Pharmaceuticals Logs HY Loss RMB118 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562067740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562067740?lang=en_us&edition=fundamental","pubTime":"2025-08-27 22:59","pubTimestamp":1756306755,"startTime":"0","endTime":"0","summary":"BRIEF-Visen Pharmaceuticals Logs HY Loss RMB118 MlnAug 27 (Reuters) - Visen Pharmaceuticals 2561.HK:HY LOSS RMB118 MILLIONFurther company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nFWN3UJ0FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2562174049","title":"Visen Pharmaceuticals Reports Increased Loss of RMB 118 Million for H1 2025; R&D and Administrative Expenses Rise Significantly","url":"https://stock-news.laohu8.com/highlight/detail?id=2562174049","media":"Reuters","labels":["executive","dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562174049?lang=en_us&edition=fundamental","pubTime":"2025-08-27 22:46","pubTimestamp":1756305998,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals Reports Increased Loss of RMB 118 Million for H1 2025; R&D and Administrative Expenses Rise Significantly. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on August 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL9Cm74T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"1170723952","title":"VISEN PHARMA-B (02561) Reports Interim Results with R&D Costs of RMB 46.621 Million, Up 19.8% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1170723952","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170723952?lang=en_us&edition=fundamental","pubTime":"2025-08-27 22:46","pubTimestamp":1756305981,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) announced its interim results for the six months ended June 30, 2025, recording other income of RMB 5.301 million during the period. Research and development costs reached RMB...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2562474035","title":"Visen Pharmaceuticals - Hy Loss RMB118 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562474035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562474035?lang=en_us&edition=fundamental","pubTime":"2025-08-27 22:35","pubTimestamp":1756305351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nFWN3UJ0FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2546422697","title":"Visen Pharmaceuticals Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546422697","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546422697?lang=en_us&edition=fundamental","pubTime":"2025-06-27 22:50","pubTimestamp":1751035813,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals held its Annual General Meeting on 27 June 2025. During the meeting, several proposals were presented and approved. The audited consolidated financial statements for the year ended 31 December 2024, along with the reports of the directors and auditors, were received. Mr. LU An-Bang was re-elected as an executive director. Additionally, the commercial supply framework agreement between Visen Pharmaceuticals HK Limited and Ascendis Pharma Europe A/S, including the transactions and proposed annual caps related to it, was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the info","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL5W6bxd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ASND","LU0320765992.SGD","02561","LU0889565916.HKD","BK1161","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2542438995","title":"Visen Pharmaceuticals to Vote on Revised Proxy Proposal at Upcoming Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542438995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542438995?lang=en_us&edition=fundamental","pubTime":"2025-06-12 23:00","pubTimestamp":1749740453,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals is set to hold its annual general meeting on June 12, 2025, at Room 2605, 1788 Square, Shanghai, China. Shareholders will vote on a revised proxy proposal, as detailed in a supplemental circular available on the company's website. The meeting will also address other resolutions as outlined in the original notice dated April 30, 2025. Shareholders can receive printed copies of the circular or change their communication preferences by contacting the company's branch registrar in Hong Kong.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on June 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL8LcGj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2542510720","title":"Visen Pharmaceuticals Secures New Supply Agreement with Ascendis Europe for Drug Packages and Auto-Injectors","url":"https://stock-news.laohu8.com/highlight/detail?id=2542510720","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542510720?lang=en_us&edition=fundamental","pubTime":"2025-06-12 22:28","pubTimestamp":1749738482,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals has announced a new contract with Ascendis Europe under a Commercial Supply Framework Agreement, effective from June 12, 2025, to December 31, 2027. The agreement involves the purchase of Drug Packages, auto-injectors, and ancillary products to meet the anticipated strong market demand for Visen's lonapegsomatropin products following its Global Offering. VISEN HK, a wholly owned subsidiary of the company, will coordinate these purchases. The terms of the agreement ensure continuous access to essential drugs for patients and healthcare providers, leveraging the financial strength and reputation of Ascendis Pharma A/S, which owns Ascendis Europe.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL5TL4sp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND","LU0109394709.USD","LU0320765992.SGD","BK1161","02561","BK4139","BK4585","LU0889565916.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}